Medical
NEW
CAR-T Cell Therapy for Mesothelioma: Penn huCART-meso Phase 1 (2026)
David Foster
May 24, 2026
Penn Abramson huCART-meso Phase 1 (NCT03054298; PMID 41566776) — fully human mesothelin CAR-T; 35% CRS, 60% stable disease, 2+ year T-cell persistence.
12 min read 7 FAQs
Read